Company Overview
Snapshot
Founded in February 2022 by Moshe Barel, Aaron Frimerman, and Shai Revzen, AccuLine operates with 11–50 employees. The company has raised $6.25 million across five funding rounds from four investors. In May 2024, AccuLine secured a grant from Google and the Israel Innovation Authority.
Business overview
AccuLine is a Health Tech & Life Sciences company focused on developing solutions for the early detection and prevention of heart attacks. Its core product, CORA, is a non-invasive, rapid, and cost-effective examination system designed to replace traditional stress tests for detecting Coronary Artery Disease (CAD). CORA analyzes the heart's electrical activity, oxygen saturation, and respiratory phase to automatically generate results. The company operates within the digital healthcare, medical devices, and diagnostics sectors, serving the healthcare industry, particularly providers, with a focus on the North American market.
Strategic signal
In September 2023, AccuLine announced a know-how license agreement with Mayo Clinic to advance the early detection of heart attacks. This collaboration signals strong institutional validation for AccuLine's technology and provides a strategic pathway for leveraging Mayo Clinic's expertise and clinical reach, accelerating the development and potential market adoption of its CORA system.
Log in to access full profile ›Company Intelligence Q&A
- What is AccuLine's primary product?
- AccuLine's primary product is CORA, a non-invasive, swift, and cost-effective examination system for the early detection of Coronary Artery Disease (CAD).
- When was AccuLine founded and by whom?
- AccuLine was founded in February 2022 by Moshe Barel, Aaron Frimerman, and Shai Revzen.
- What significant partnership did AccuLine announce in September 2023?
- In September 2023, AccuLine announced a know-how license agreement with Mayo Clinic to advance the early detection of heart attacks.
- Which organizations provided grants to AccuLine in May 2024?
- In May 2024, AccuLine received grants from Google and the Israel Innovation Authority.
- What is the total capital raised by AccuLine?
- AccuLine has raised a total of $6.25 million across five funding rounds.